One To Watch

XOMA Royalty

Company Overview

A biotech royalty aggregator that acquires milestone and royalty interests across diversified biopharma pipelines, XOMA Royalty has agreed to be acquired by Ligand Pharmaceuticals for approximately $739 million in a deal expected to close in Q3 2026. XOMA's model is capital-light and deliberately non-operational: it buys economic rights to third-party drug programs at various stages of development, collecting milestones as assets advance and royalties once they reach market. In 2025, the company delivered over $50 million in total cash receipts — royalties up 68% year-on-year to $33.6 million — validating a portfolio that now spans more than two dozen assets added in that year alone.

Headquarters and Global Presence

XOMA Royalty is headquartered in San Francisco, California. Its portfolio has regulatory exposure across both US and European markets, with pending EMA decisions on two assets — OJEMDA and MIPLYFFA — among its near-term catalysts.

Founding and History

XOMA Corporation traces its origins to the 1980s as an antibody drug developer; the royalty-aggregator model represents a strategic pivot that crystallized under the XOMA Royalty identity. The company has since repositioned itself entirely around acquiring royalty and milestone streams from biotech and pharma partners rather than developing drugs itself. The announced Ligand acquisition at $39.00 per share — a total equity value of roughly $739 million — marks the culmination of that model's value creation.

Therapy Areas and Focus

XOMA Royalty's portfolio is deliberately therapy-agnostic, which is intrinsic to the aggregator model: diversification across indications reduces the binary risk of any single readout. That said, rare diseases and oncology feature prominently in the active pipeline, with assets targeting primary sclerosing cholangitis (PSC), tumor-related hearing impairment, and two programs awaiting EMA review. The five Phase II/Phase III programs added in 2025 signal a deliberate tilt toward late-stage assets where milestone and royalty timelines are shorter.

Technology Platforms and Modalities

XOMA does not develop drug candidates or own proprietary discovery platforms in the conventional sense. Its two core competencies are deal origination — identifying undervalued royalty streams held by academic institutions, small biotechs, or spin-outs — and portfolio management, including the two platform technology interests added in 2025. That approach mirrors the Royalty Pharma model at smaller scale, and the Ligand acquisition signals that scale consolidation is now the dominant logic in this corner of biopharma finance.

Key Pipeline and Programs

Volixibat is an oral apical sodium-dependent bile acid transporter (ASBT) inhibitor being developed by a partner for primary sclerosing cholangitis, a rare and progressive cholestatic liver disease with no approved therapy. XOMA holds royalty rights; Phase IIb data are expected in Q2 2026, making it the nearest-term clinical catalyst in the portfolio.

Ersodetug is a partner-developed asset targeting tumor-related hearing impairment, a condition affecting patients treated with platinum-based chemotherapy. Phase III data are anticipated in the second half of 2026 — the highest-stage readout in XOMA's near-term calendar.

OJEMDA and MIPLYFFA are two assets with pending EMA regulatory decisions in 2026. Both are further along the commercialization curve, meaning favorable rulings would convert directly into royalty-generating events rather than distant developmental milestones.

Recent Developments

The defining event of the past year is the April 27, 2026 announcement that Ligand Pharmaceuticals will acquire XOMA Royalty for $39.00 per share in cash — a transaction valued at approximately $739 million and expected to close in Q3 2026. Full-year 2025 financials, reported ahead of the deal announcement, showed total cash receipts exceeding $50 million, with royalty income up 68% versus 2024 — the strongest growth signal in the company's recent history. In January 2026, Jeffrey Trigilio joined as CFO, replacing Thomas Burns; Trigilio previously held CFO/COO roles at Obsidian Therapeutics and CFO at Cullinan Therapeutics.

Key Personnel

Owen Hughes serves as Chief Executive Officer, having steered XOMA Royalty through its portfolio expansion phase and the Ligand sale process. Jeffrey Trigilio was appointed Chief Financial Officer in January 2026, bringing prior financial leadership experience from Obsidian Therapeutics and Cullinan Therapeutics. Jack L. Wyszomierski serves as Chairman of the Board, providing governance oversight through the pending acquisition.

Strategic Partnerships

XOMA Royalty's entire business model is built on partnerships: it acquires economic rights from biotechs and institutions that retain operational control of their programs, allowing partners to monetize future cash flows upfront. The seven acquisitions completed in 2025, adding 22 assets and two platform technology interests, reflect active deal flow rather than organic R&D. The pending Ligand acquisition will absorb this portfolio into a larger royalty platform with greater deal-making firepower.

FAQ Section

Ligand's $739 million all-cash offer reflects the strategic logic of consolidating royalty portfolios — greater scale reduces the cost of capital, accelerates deal sourcing, and diversifies readout risk across more assets. For XOMA stockholders, the $39.00 per share price represents a clean exit at a premium following years of portfolio-building. The deal reinforces a broader consolidation trend in the royalty aggregator space, where Royalty Pharma, Ligand, and a handful of smaller players are competing for the same upstream deal flow.

Volixibat blocks the apical sodium-dependent bile acid transporter in the ileum, reducing bile acid recirculation and the resulting cholestatic liver damage. Primary sclerosing cholangitis is a chronic inflammatory bile duct disease with no approved pharmacotherapy and a high rate of progression to cirrhosis and cholangiocarcinoma. A positive Phase IIb readout in Q2 2026 would be a significant signal for an indication where the clinical bar for efficacy has historically proved difficult to clear.

XOMA carries none of the clinical execution or manufacturing risk that burdens traditional biotechs: it acquires financial rights to programs developed and operated by third parties, earning milestones on trial progression and royalties on sales. This means its upside is capped relative to full drug ownership, but its downside from any single program failure is limited to the acquisition cost of that royalty stream. The 2025 portfolio expansion — 22 assets, seven acquisitions, two platform technology interests — illustrates how the model scales through deal volume rather than headcount or R&D spend.

Ersodetug is being developed by a partner to prevent or treat hearing loss in cancer patients receiving platinum-based chemotherapy — a condition affecting a substantial proportion of pediatric and adult oncology patients with no approved intervention. The Phase III data expected in the second half of 2026 represent the highest-stage clinical event in XOMA's near-term pipeline and, if positive, would be a direct precursor to a regulatory filing. For XOMA, a successful outcome would trigger milestone payments and eventually royalties on a drug addressing a well-defined unmet need in oncology supportive care.

Therapy-area diversification is deliberate and structural: the aggregator model explicitly avoids concentration in any single indication, reducing the portfolio's sensitivity to any one trial readout. The 2025 additions spanned rare liver disease, oncology, and assets with pending European regulatory decisions — OJEMDA and MIPLYFFA — suggesting a mix of near-commercial and mid-stage programs. The five Phase II/Phase III assets added in 2025 represent a meaningful tilt toward later-stage rights where cash conversion timelines are shorter.

XOMA is effectively in a wind-down as an independent entity, with the Ligand acquisition targeted for Q3 2026 closure. Before that, three substantive catalysts are scheduled: Phase IIb volixibat data in PSC (Q2 2026), Phase III ersodetug data in tumor hearing impairment (H2 2026), and EMA decisions on OJEMDA and MIPLYFFA. Each positive readout would generate milestone receipts that flow through XOMA's books prior to closing, giving existing stockholders incremental value in the interim period.

The profile is defined by a tight cluster of near-term events and one dominant corporate risk. Key watchpoints include:

Volixibat Phase IIb data in PSC (Q2 2026): the nearest binary event, in an indication where prior ASBT programs have had mixed results.
Ersodetug Phase III readout in tumor hearing impairment (H2 2026): the highest-stage clinical catalyst; a positive outcome would support a regulatory filing and milestone trigger.
EMA decisions on OJEMDA and MIPLYFFA: approval would convert these from pipeline to revenue-generating royalty assets.
Ligand deal closure risk: any regulatory, financing, or shareholder obstacle to the Q3 2026 target close could create uncertainty for XOMA shareholders.

Want to Update your Company's Profile?